Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 (camrelizumab) in advanced solid tumors
NCT02742935Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2016
- Primary completion
- May 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab in solid tumor, sponsored by Hengrui. Primary endpoint: Severity of adverse events at 28 days. Started Apr 2016; status: completed.
02
Drugs
camrelizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02742935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742935.